Related Articles
Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience
Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: A phase II study
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: A phase II trial
A retrospective study of docetaxel and bevacizumab as a second‑ or later-line chemotherapy for non-small cell lung cancer
Clinical predictor of survival following docetaxel‑based chemotherapy